Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Receives CE-IVD Mark for Its Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19
SOUTH SAN FRANCISCO, Calif. , Jan. 21, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company has received the CE-IVD mark for its Advanta™ Dx
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2020 Financial Results
SOUTH SAN FRANCISCO, Calif. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report fourth quarter and full year 2020 financial results
View HTML
Toggle Summary New Data Published in Gastroenterology Demonstrate the Power of Fluidigm’s Imaging Mass Cytometry on the Hyperion Imaging System to Identify Novel Targets for Pancreatic Cancer Therapy
Study Highlighting IMC Application in Both Protein and RNA Detection Conducted by Researchers at Fluidigm C enter of Excellence for  Imaging Mass Cytometry at Georgetown Lombardi Comprehensive Cancer Center SOUTH SAN FRANCISCO, Calif. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation
View HTML
Toggle Summary Dr. Ana K. Stankovic, MD, PhD, Appointed to Fluidigm Board of Directors
SOUTH SAN FRANCISCO, Calif. , Dec. 15, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the appointment of Dr. Ana K.
View HTML
Toggle Summary Key Regulatory Body in India Grants Commercial License for Fluidigm Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay
Fluidigm Assay is Among First Saliva-Based COVID-19 Tests Licensed for Use by Designated Labs in India SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive
View HTML
Toggle Summary Fluidigm to Participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company’s management will participate in the Piper Sandler
View HTML
Toggle Summary Study Utilizing Imaging Mass Cytometry Details Changes in Lung Tissue Architecture at the Single-Cell Level in Patients with COVID-19
Weill Cornell Medicine Researchers Utilize Fluidigm Hyperion Imaging System to Identify a Phenotype of Immune Cell Activity Distinct from Other Lung Infections A Framework for Data-Driven Spatial Understanding of Lung Pathology to Inform New Treatment Approaches for COVID-19 SOUTH SAN FRANCISCO,
View HTML
Toggle Summary Fluidigm COVID-19 Community Connect Program Builds a Network of Testing Partners to Increase Access of Saliva-Based SARS-CoV-2 Testing for Communities
SOUTH SAN FRANCISCO, Calif. , Nov. 17, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced COVID-19 Community Connect, a program to link federal, state and local
View HTML
Toggle Summary Fluidigm to Present at Upcoming Health Care Investor Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in investor meetings and
View HTML
Toggle Summary Fluidigm Announces Third Quarter 2020 Financial Results
Third   Q uarter T otal R evenue I n creased 50   P ercent to $ 39 .9   M illion Third Q uarter P roduct and Service R evenue I ncreased 34   P ercent to   $35 . 3 M illion   D riven by COVID-19 T esting GAAP N et L oss in the T hird Q uarter Was $6.0   M illion ; Non-GAAP N et I ncome W as $2.5  
View HTML